DISCLAIMER: This product is strictly for research use only. It is meant solely for laboratory testing and in vitro studies-not for use in or on humans or animals. All details provided on this site are for educational purposes. It is illegal to introduce this substance into the body. Only licensed professionals should handle it. This item is not intended to be used as a drug, supplement, or cosmetic, and must not be misrepresented as such.
CJC-1295 (No DAC) + Ipamorelin + Tesamorelin (Blend)
CJC-1295 (no DAC), Ipamorelin, and Tesamorelin are studied together to boost natural growth hormone and IGF-1 levels through complementary pathways that support fat loss, recovery, and hormone balance.
Quantity: 1
All peptides arrive in powdered form for stability
Third-Party Verified Purity
Each batch is tested and certified to meet or exceed 99% purity standards.
Made in the USA
Produced in United States WHO/GMP and ISO 9001:2015 certified facilities.
Rigorous Quality Control
Double-tested to ensure the highest quality for the most effective research.
What is CJC-1295 (No DAC) + Ipamorelin + Tesamorelin (Blend)?
CJC-1295 without Drug Affinity Complex (no DAC) is a short-acting analog of growth hormone–releasing hormone (GHRH) that stimulates the pituitary to release growth hormone (GH) in a natural, pulsatile pattern. Ipamorelin is a selective growth hormone secretagogue (GHS) that activates ghrelin receptors to increase GH secretion without significantly affecting cortisol or prolactin. Tesamorelin is a stabilized 44–amino acid GHRH analog that increases GH release and is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy. In research settings, this combination is explored for its potential to enhance GH output, IGF-1 production, and tissue recovery through multiple complementary pathways.
Potential Benefits Shown in Studies
Possible benefits of CJC‑1295 (no DAC) + Ipamorelin + Tesamorelin Blend:
- Maximized GH & IGF‑1 Release
- Accelerated Fat Loss, especially visceral adipose tissue
- Improved Sleep Quality & Mood
- Increased Energy & Cognitive Function
- Enhanced Cellular Repair & Regeneration
- Sustained, Natural GH Production
Mechanisms of Action
CJC-1295 (no DAC) + Ipamorelin + Tesamorelin may work together by:
- CJC-1295 (no DAC): Binding to GHRH receptors to produce short bursts of GH that mimic physiologic release
- Ipamorelin: Activating ghrelin receptors (GHS-R1a) to trigger GH release without large increases in cortisol or prolactin
- Tesamorelin: Stimulating GHRH receptors with a longer-acting profile, increasing GH secretion and promoting fat metabolism
- Increasing circulating IGF-1 to support protein synthesis, collagen formation, and tissue regeneration
- Supporting muscle preservation, fat utilization, and connective tissue health in research models
- Combining short-acting (CJC-1295 no DAC) and longer-acting (Tesamorelin) GHRH analogs for layered GH stimulation
Molecular Structure of Blend Components
CJC-1295 (No DAC) Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser
Molecular Properties
CJC-1295 (No DAC) + Ipamorelin + Tesamorelin (Blend) Research Highlights
Combining GHRH analogs (CJC‑1295, Tesamorelin) with a ghrelin receptor agonist (Ipamorelin) boosts growth hormone and IGF‑1 output via dual pathways.
Source: smithfieldtimes
Tesamorelin is FDA-approved for reducing visceral fat in HIV-associated lipodystrophy, with effects on abdominal adipose tissue confirmed in randomized controlled trials.
Source: jamanetwork
Ipamorelin enhances GH secretion without raising cortisol or prolactin, making it safer than earlier GHRP options.
Source: wikipedia
CJC‑1295 without DAC is a short-acting analog of GHRH that reproduces the body’s natural growth hormone (GH) pulse patterns, with a half-life of around 30 minutes.
Source: pep-pedia
Its short duration allows for frequent administration that avoids pituitary down-regulation—a key advantage for maintaining physiologic GH sensitivity.
Source: hkroids
Used in conjunction with GHRP peptides like Ipamorelin, CJC‑1295 (no DAC) can enhance GH pulse amplitude and stimulate downstream IGF‑1 signaling for anabolic effects.
Source: thepeptidereport
Clinical and preclinical studies have linked CJC‑1295 (general notes across versions) to increases in GH/IGF‑1, improvements in body composition, sleep, and anti-aging markers—though human data remains limited for No DAC specifically.
Source: peptideinstitute
Ipamorelin binds specifically to the ghrelin receptors in the pituitary, inducing growth hormone (GH) release without significantly impacting cortisol, ACTH, or prolactin—offering a cleaner profile compared to other GHRPs.
Source: pep-pedia
Animal studies indicate that Ipamorelin may counteract glucocorticoid-induced muscle catabolism and increase bone mineral content, particularly enhancing tibial growth and bone density in female rats.
Source: sagepub
Ipamorelin closely mimics natural GH secretion patterns by delivering targeted pulses, which helps maintain physiological hormone balance and potentially improves metabolic responses.
Source: propeptidesource
Due to its selectivity and minimal hormonal side effects, Ipamorelin is under investigation as a research tool for muscle recovery, anti-aging protocols, and metabolic studies.
Source: regentherapy
Tesamorelin (Egrifta®) is FDA-approved for reducing visceral adipose tissue (VAT) in patients with HIV-associated lipodystrophy, with clinical trials demonstrating significant VAT loss and improvements in body composition, lipid profile, and insulin sensitivity.
Source: Metical Anti-Aging Evidence
Emerging research is exploring Tesamorelin’s effects beyond HIV lipodystrophy, including reducing hepatic steatosis and liver fibrosis in NAFLD, improving cognitive function, insulin resistance, and other aging-related metabolic markers.
Current Phase II trials are evaluating Tesamorelin’s potential in improving cognitive function in aging HIV populations, and in enhancing motor and sensory recovery after peripheral nerve injuries.
Tesamorelin has been shown to improve lipid metabolism—lowering triglycerides by ~15% and increasing HDL—while maintaining or even enhancing insulin sensitivity, and improving glucose homeostasis.